Innovative technologies in prophylaxis, diagnostics and treatment of cardiovascular diseases

Abstract

Intoroducing innovative approaches into the clinical practice leads to a substantial improvement of treatment results for socially important diseases and to a reduction of rehabilitation costs. New technologies are used in the prophylaxis as well as treatment of cardiovascular diseases. This article gives a brief description of the innovative projects in various stages of realization, aimed to develop high-technology methods for screening, diagnostics and treatment of cardiovascular diseases. We especially focus on the description of the social and economic effect expected from introducing the new products, technologies and services.

Keywords

innovative technologies / cardiology / cardiosurgery / ischemic heart disease

References

[1] Арефьев Д.В., Белостоцкая И.С., Вольева Н.С. и др. Гибридные макромолекулярные антиоксиданты на основе гидрофильных полимеров и пространственно-затрудненных фенолов // Изв. АН. Серия хим. 2007. № 4. С. 751-760.

[2] Галагудза М.М., Папаян Г.В., Власов Т.Д. и др. Визуализация начальных проявлений ишемического повреждения сердца с помощью аутофлуоресцентной органоскопии // Per. кров, и микроцирк. 2009. Т. 8. № 2 (30). С. 76-78.

[3] Королев Д.В., Александров И.В., Галагудза М.М. и др. Автоматизация получения и обработки данных физиологического эксперимента // Per. кров, и микроцирк. 2008. Т. 7. № 2(26). С. 79-84.

[4] Хрусталева Р.С., Фармаковский Б.В., Кузнецов П.А. и др. Применение новых магнитных наноматериалов для защиты биологических объектов от влияния электромагнитного излучения // Нанотехнологии в биологии и медицине / Под ред. Е.В. Шляхто. СПб.: Любавич, 2009. С. 213-225.

[5] Ako J., Bormeau H.N., Honda Y. et al. Design criteria for the ideal drug-eluting stent // Am. J. Cardiol. 2007. Vol. 100. № 8B. P. 3M-9M.

[6] Anisimov S.V. Selecting a proper platform for microarray experiment // Oligonucleotide array sequence analysis / Ed. by M.K. Moretti, L.J. Rizzo. USA: Nova Publishers, 2008.

[7] Galagudza M.M., Korolev D.V., Sonin D.L. et al. Targeted drug delivery to ischemic heart with use of nanoparticulate carriers: concepts, pitfalls and perspectives // J. Manufact. Technol. Manag. 2009 (in press).

[8] Gulbins H., Kreuzer E., Reichart B. Homografts: a review // Expert Rev. Cardiovasc. Ther. 2003. Vol. l.№ 4. P. 533-539.

[9] Goffin Y.A., Van Hoeck В., Jashari R. et al. Banking of cryopreserved heart valves in Europe: assessment of a 10-year operation in the European Homograft Bank (EHB) // J. Heart Valve Dis. 2000. Vol. 9. № 2. P. 207-214.

[10] Langeveld В., Roks A.J., Tio R.A. et al. Rat abdominal aorta stenting: a new and reliable small animal model for in-stent restenosis // J. Vase. Res. 2004. Vol. 41. №5. P. 377-386.

[11] Nicolini F., Beghi C, Muscari C. et al. Myocardial protection in adult cardiac surgery: current options and future challenges // Eur. J. Cardiothorac. Surg. 2003. Vol. 24. № 6. P. 986-993.

[12] Petrishchev N.N. Autofluorescence of tissue under normal and pathological conditions // Proc. of 9th Annual Congress the Korean Photodynamic Association and the 4th International & 1 st Asia, Korea-Japan Photodynamic Therapy Symposium, 22- 23 August, Seoul, Korea. 2009. P. 26-28.

[13] Raman R.N., Pivetti CD., Rubenchik A.M. et al. Evaluation of the contribution of the renal capsule and cortex to kidney autofluorescence intensity under ultraviolet excitation // J. Biomed. Opt. 2009. Vol. 14. № 2. P. 020505.

[14] Shen Y, Wu B.L. Microarray-based genomic DNA profiling technologies in clinical molecular diagnostics // Clin. Chem. 2009. Vol. 55. № 4. P. 659-669.

[15] Vance J.E., Steenbergen R. Metabolism and functions of phosphatidylserine // Prog. Lipid Res. 2005. Vol. 44. № 4. P. 207-234.

RIGHTS & PERMISSIONS

Shlakhto E.V., Tsyrlin V.A., Petrischev N.N., Galagudza M.M., Zverev D.A., Anisimov S.V., Kurapeev D.I., Korolev D.V., Lebedev D.S.